Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.34 |
| ▸ | MAPT | P10636 | 5/20 | 0.34 |
| ▸ | RAB9A | P51151 | 5/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | PLCG2 | P16885 | 1/20 | 0.33 |
| ▸ | AHR | P35869 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6889892 | 0.70 | IDO1 (0.33) | NPC1MAPTRAB9AAHRIDO1 | |
| SCHEMBL6887963 | 0.68 | — | — | |
| SCHEMBL6887487 | 0.65 | ERN1 (0.38) | NPC1MAPTRAB9ACYP3A4 | |
| SCHEMBL6888757 | 0.64 | NOTUM (0.41) | MAPT | |
| SCHEMBL6883982 | 0.63 | MAPK1 (0.36) | NPC1MAPTRAB9ACYP1A2 | |
| SCHEMBL6888453 | 0.62 | RAB9A (0.52) | NPC1MAPTRAB9A | |
| SCHEMBL7691429 | 0.60 | CA2 (0.38) | NPC1MAPTRAB9A | |
| SCHEMBL28812275 | 0.60 | ALDH1A1 (0.35) | CYP3A4 | |
| SCHEMBL6889201 | 0.60 | LMNA (0.39) | NPC1MAPTRAB9ACYP1A2 | |
| SCHEMBL6890028 | 0.60 | PPARA (0.41) | NPC1MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727950-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF MYCOBACTERIAL INFECTIONS | GlaxoSmithKline Intellectual Property Development Ltd (GB) | 2026-04-22 | — | — | EP | claimed |
| US-20260048047-A1 | SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE | SCRIPPS RESEARCH INST (US) | 2026-02-19 | — | — | US | claimed |
| WO-2025096495-A1 | ARYL FLUOROSULFATE-BASED INHIBITORS AS NOVEL ANTITUBERCULAR AGENTS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2025-05-08 | — | — | WO | claimed |
| US-20250129084-A1 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2025-04-24 | — | — | US | claimed |
| EP-4486454-A1 | COMPOUNDS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2025-01-08 | — | — | EP | claimed |
| WO-2024256554-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF MYCOBACTERIAL INFECTIONS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-12-19 | — | — | WO | claimed |
| US-20240307385-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-09-19 | — | — | US | claimed |
| US-11969423-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-04-30 | — | — | US | claimed |
| WO-2024030121-A1 | SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2024-02-08 | — | — | WO | claimed |
| WO-2023156648-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-08-24 | — | — | WO | claimed |
| CN-111225910-B | Novel compounds | 葛兰素史密斯克莱知识产权发展有限公司 | 2023-03-24 | — | — | CN | claimed |
| CN-110997651-B | Novel tetrazole compounds and their use in the treatment of tuberculosis | 葛兰素史密斯克莱知识产权发展有限公司 | 2023-01-03 | — | — | CN | claimed |
| CN-110997680-B | Novel compound | 葛兰素史密斯克莱知识产权发展有限公司 | 2022-10-21 | — | — | CN | claimed |
| EP-4029870-A1 | TRICYCLIC BENZOXABOROLE COMPOUNDS AND USES THEREOF | GlaxoSmithKline Intellectual Property (No.2) Limited (GB) | 2022-07-20 | — | — | EP | claimed |
| US-11254689-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-02-22 | — | — | US | claimed |
| US-11253499-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-02-22 | — | — | US | claimed |
| EP-4743446-A1 | NITRO-CONTAINING COMPOUNDS THAT KILL MYCOBACTERIA | Board of Trustees of Michigan State University (US) | 2026-05-20 | — | — | EP | disclosed |
| EP-4727950-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF MYCOBACTERIAL INFECTIONS | GlaxoSmithKline Intellectual Property Development Ltd (GB) | 2026-04-22 | — | — | EP | disclosed |
| US-20080139577-A1 | Nitroheteroaryl-containing rifamycin derivatives | CUMBRE PHARMACEUTICALS INC. (US) | 2008-06-12 | — | — | US | disclosed |
| WO-2008008480-A2 | NITROHETEROARYL-CONTAINING RIFAMYCIN DERIVATIVES | CUMBRE PHARMACEUTICALS INC. (US) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129084-A1 | Compounds | CFTR, TBCA, TBCD | NPC1 56/4885MAPT 217/4885RAB9A 1145/4885 |
| US-20240307385-A1 | NOVEL COMPOUNDS | FNTB, SDHA, FDPS | NPC1 88/4885MAPT 1598/4885RAB9A 1414/4885 |
| US-11253499-B2 | Compounds | SDHA, SDHB, FDPS | NPC1 114/4885MAPT 881/4885RAB9A 2120/4885 |
| US-20260048047-A1 | SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE | FNTB, PDE7A, TBL3 | NPC1 99/4885MAPT 4455/4885RAB9A 544/4885 |
| US-11254689-B2 | Compounds | SDHA, SDHB, FDPS | NPC1 114/4885MAPT 881/4885RAB9A 2120/4885 |
| US-20080139577-A1 | Nitroheteroaryl-containing rifamycin derivatives | NRDC, FNTB, RIF1 | NPC1 869/4885MAPT 2006/4885RAB9A 973/4885 |
| US-11969423-B2 | Compounds | SDHA, SDHB, FDPS | NPC1 114/4885MAPT 881/4885RAB9A 2120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.